Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY) Despite 'Disappointing' GLP-1 Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
January 17, 2025 9:44 AM ESTLeerink Partners analyst Andrew Berens reiterated an Outperform rating and $950.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments " Bottom Line: NVOs (Not Rated) Ph3b STEP UP trial of a higher dose, 7.2 mg semaglutide achieved 20.7% (18.3% pbo-adj.) weight loss after 72 weeks in nondiabetic obese patients. The approved max dose of semaglutide in nondiabetic obesity is 2.4 mg. The weight loss exhibited with... More
